Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 09/27 05:35:14 pm
1637.5 GBp   +0.24%
09/26 GLAXOSMITHKLINE : King's College London - Funding for new immunother..
09/23DJGLAXOSMITHKLINE : Files US Regulatory Application for Sirukumab in R..
09/23 GLAXOSMITHKLINE : GSK announces US regulatory submission for sirukum..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline: European Commission Authorizes Nimenix

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 02:24pm CEST

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
09/26 GLAXOSMITHKLINE : King's College London - Funding for new immunotherapy company
09/23DJGLAXOSMITHKLINE : Files US Regulatory Application for Sirukumab in Rheumatoid Ar..
09/23 GLAXOSMITHKLINE : GSK announces US regulatory submission for sirukumab in rheuma..
09/23 GLAXOSMITHKLINE : Files Licence Application For Arthritis Treatment
09/23 GLAXOSMITHKLINE : US Regulatory Submission for sirukumab in RA
09/23DJGLAXOSMITHKLINE : GSK Submits for Subcutaneous Formulation of Benlysta in US, Eu..
09/23 GLAXOSMITHKLINE : Glaxo Files US, European Submissions For Benlysta In Systemic ..
09/23 GLAXOSMITHKLINE : GSK announces regulatory submissions for subcutaneous formulat..
09/21 Emma named as new Glaxo
09/21 Emma named as new Glaxo chief
More news
Sector news : Pharmaceuticals - NEC
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 Whose Drug Pipeline Impresses Most? A Rough Comparison Of GlaxoSmithKline And..
09/26 GILEAD : Ways To Unlock Shareholder Value
09/23 Janssen submits marketing application in U.S. for sirukumab for rheumatoid ar..
09/22 Expect Glaxo To Increase Consumer Focus As Walmsley Takes Driving Seat
09/20 A Unique Method To Value Dividend Stocks Based On Expected Growth
Advertisement
Financials ( GBP)
Sales 2016 26 978 M
EBIT 2016 7 126 M
Net income 2016 2 684 M
Debt 2016 13 482 M
Yield 2016 4,90%
P/E ratio 2016 35,50
P/E ratio 2017 21,33
EV / Sales 2016 3,45x
EV / Sales 2017 3,28x
Capitalization 79 642 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 17,5  GBP
Spread / Average Target 6,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Moncef Slaoui Executive Director & Chairman-Global Vaccines
Roy Malcolm Anderson Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC20.39%103 357
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results